GILDbenzinga

Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on December 19, 2024 by benzinga